Morepen Laboratories Limited has informed the Exchange regarding a press release dated May 13, 2025, titled "Morepen Board Proposed Dividend After 23 Years Scores Highest PAT of Rs. 118 in FY25".
MOREPENLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Morepen Laboratories has announced its first dividend in 23 years at Rs. 0.20 per share, subject to shareholder approval at the upcoming AGM. For FY25, the company reported its highest-ever profit after tax (PAT) of Rs. 118 crore, with gross revenue rising 7.4% year-on-year to Rs. 1,830 crore (from Rs. 1,704 crore in FY24). EBITDA grew 21.6% to Rs. 118 crore, and earnings per share climbed 17% to Rs. 2.20. The API business contributed Rs. 989 crore, while the Medical Devices segment grew 12% to Rs. 496 crore, supported by exports to 80+ countries.
The resumption of dividends after a 23-year gap signals strong cash flow and management confidence, while record PAT and 17% EPS growth could be viewed positively by retail investors. The stock may see short-term interest from income-seeking shareholders, though the dividend amount itself is modest.